What is Neuronetics's earnings per share (EPS)?

Neuronetics (STIM) reported diluted earnings per share of $-0.59 for fiscal year 2025. This represents a 57.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Neuronetics Financials

STIM

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Neuronetics (STIM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 30/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Neuronetics has an operating margin of -21.1%, meaning the company retains $-21 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -46.2% the prior year.

Growth

100

Neuronetics's revenue surged 99.2% year-over-year to $149.2M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Neuronetics has a moderate D/E ratio of 2.94. This balance of debt and equity financing earns a leverage score of 42/100.

Liquidity

Neuronetics's current ratio of 2.02 indicates adequate short-term liquidity, earning a score of 37/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Neuronetics generated -$20.4M in operating cash flow, capex of $801K consumed most of it, leaving -$21.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Neuronetics generates a -174.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -157.8% the prior year.

Piotroski F-Score Neutral

4/9

Neuronetics passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.52x

For every $1 of reported earnings, Neuronetics generates $0.52 in operating cash flow (-$20.4M OCF vs -$39.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-4.1x

Neuronetics earns $-4.1 in operating income for every $1 of interest expense (-$31.4M vs $7.6M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$149.2M

YoY+99.2%

5Y CAGR+24.8%

Neuronetics generated $149.2M in revenue in fiscal year 2025. This represents an increase of 99.2% from the prior year.

EBITDA

-$28.0M

YoY+13.9%

Neuronetics's EBITDA was -$28.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 13.9% from the prior year.

Net Income

-$39.0M

YoY+10.8%

Neuronetics reported -$39.0M in net income in fiscal year 2025. This represents an increase of 10.8% from the prior year.

EPS (Diluted)

$-0.59

YoY+57.2%

Neuronetics earned $-0.59 per diluted share (EPS) in fiscal year 2025. This represents an increase of 57.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$21.2M

YoY+34.8%

Neuronetics generated -$21.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 34.8% from the prior year.

Cash & Debt

$28.1M

YoY+52.4%

5Y CAGR-10.5%

Neuronetics held $28.1M in cash against $65.8M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

69M

YoY+23.9%

5Y CAGR+29.3%

Neuronetics had 69M shares outstanding in fiscal year 2025. This represents an increase of 23.9% from the prior year.

Margins & Returns

Gross Margin

48.5%

YoY-23.8pp

5Y CAGR-28.1pp

Neuronetics's gross margin was 48.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 23.8 percentage points from the prior year.

Operating Margin

-21.1%

YoY+25.1pp

5Y CAGR+24.2pp

Neuronetics's operating margin was -21.1% in fiscal year 2025, reflecting core business profitability. This is up 25.1 percentage points from the prior year.

Net Margin

-26.2%

YoY+32.2pp

5Y CAGR+29.6pp

Neuronetics's net profit margin was -26.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 32.2 percentage points from the prior year.

Return on Equity

-174.3%

YoY-16.5pp

5Y CAGR-66.6pp

Neuronetics's ROE was -174.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 16.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$6.6M

YoY-48.4%

5Y CAGR-6.5%

Neuronetics invested $6.6M in research and development in fiscal year 2025. This represents a decrease of 48.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$801K

YoY-45.4%

5Y CAGR+1.9%

Neuronetics invested $801K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 45.4% from the prior year.

STIM Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$149.2M+99.2%	$74.9M+5.0%	$71.3M+9.4%	$65.2M+17.9%	$55.3M+12.3%	$49.2M
Cost of Revenue	$76.8M+270.7%	$20.7M+5.5%	$19.6M+26.9%	$15.5M+32.9%	$11.7M+0.9%	$11.6M
Gross Profit	$72.3M+33.5%	$54.2M+4.8%	$51.7M+4.0%	$49.7M+13.9%	$43.7M+15.8%	$37.7M
R&D Expenses	$6.6M-48.4%	$12.8M+34.2%	$9.5M+1.9%	$9.3M+17.8%	$7.9M-13.9%	$9.2M
SG&A Expenses	$49.7M+63.9%	$30.3M+19.3%	$25.4M-0.4%	$25.5M-0.1%	$25.6M+40.1%	$18.2M
Operating Income	-$31.4M+9.0%	-$34.6M-13.1%	-$30.6M+13.0%	-$35.1M-27.4%	-$27.6M-23.6%	-$22.3M
Interest Expense	$7.6M+4.3%	$7.3M+34.3%	$5.4M+27.6%	$4.3M+5.8%	$4.0M-11.1%	$4.5M
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$39.0M+10.8%	-$43.7M-44.8%	-$30.2M+18.8%	-$37.2M-19.1%	-$31.2M-13.6%	-$27.5M
EPS (Diluted)	$-0.59+57.2%	$-1.38-31.4%	$-1.05+23.9%	$-1.38-13.1%	$-1.22+16.4%	$-1.46

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$41.8M+12.0%	$37.3M-2.1%	$38.1M+19.2%	$32.0M+42.2%	$22.5M+21.4%	$18.5M+12.6%	$16.4M-5.6%	$17.4M
Cost of Revenue	$20.1M-0.6%	$20.2M-0.8%	$20.4M+25.3%	$16.2M+113.6%	$7.6M+67.8%	$4.5M+6.0%	$4.3M-1.3%	$4.3M
Gross Profit	$21.7M+26.9%	$17.1M-3.7%	$17.8M+12.8%	$15.7M+5.7%	$14.9M+6.4%	$14.0M+15.0%	$12.2M-6.9%	$13.1M
R&D Expenses	$1.7M+10.8%	$1.5M-16.4%	$1.8M+11.3%	$1.6M-72.0%	$5.8M+138.9%	$2.4M+8.1%	$2.2M-4.9%	$2.3M
SG&A Expenses	$13.3M+20.4%	$11.1M-8.8%	$12.2M-7.5%	$13.1M+10.2%	$11.9M+89.5%	$6.3M+2.3%	$6.1M+3.2%	$6.0M
Operating Income	-$5.0M+31.1%	-$7.3M+9.1%	-$8.1M+26.8%	-$11.0M+4.0%	-$11.5M-48.4%	-$7.7M+9.2%	-$8.5M-24.0%	-$6.9M
Interest Expense	$1.5M-31.9%	$2.2M+12.0%	$2.0M+2.4%	$1.9M+9.4%	$1.8M+1.9%	$1.7M-12.8%	$2.0M+8.3%	$1.8M
Income Tax	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A
Net Income	-$7.2M+20.9%	-$9.0M+10.6%	-$10.1M+20.2%	-$12.7M-0.1%	-$12.7M+5.1%	-$13.3M-35.7%	-$9.8M-24.9%	-$7.9M
EPS (Diluted)	N/A	$-0.13+13.3%	$-0.15+28.6%	$-0.21	N/A	$-0.44-33.3%	$-0.33-22.2%	$-0.27

STIM Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$141.6M+0.5%	$140.9M+21.6%	$115.8M-0.9%	$116.9M-17.2%	$141.2M+79.5%	$78.7M
Current Assets	$61.6M+5.9%	$58.1M-38.0%	$93.8M-5.0%	$98.8M-14.4%	$115.3M+77.4%	$65.0M
Cash & Equivalents	$28.1M+52.4%	$18.5M-69.1%	$59.7M-15.2%	$70.3M-25.3%	$94.1M+92.3%	$49.0M
Inventory	$4.3M+1.9%	$4.2M-47.5%	$8.1M-9.1%	$8.9M+35.6%	$6.6M+76.4%	$3.7M
Accounts Receivable	$16.5M-29.5%	$23.4M+48.0%	$15.8M+16.1%	$13.6M+76.4%	$7.7M+7.5%	$7.2M
Goodwill	$23.6M+26.8%	$18.6M	N/A	N/A	N/A	N/A
Total Liabilities	$115.3M+5.7%	$109.1M+33.6%	$81.6M+36.5%	$59.8M+6.7%	$56.0M+5.4%	$53.2M
Current Liabilities	$30.5M-2.4%	$31.3M+57.8%	$19.8M-40.3%	$33.2M+111.4%	$15.7M+14.8%	$13.7M
Long-Term Debt	$65.8M+19.3%	$55.2M-7.0%	$59.3M+159.7%	$22.8M-35.4%	$35.3M+2.1%	$34.6M
Total Equity	$22.4M-19.2%	$27.7M-19.0%	$34.2M-40.1%	$57.1M-33.0%	$85.2M+234.1%	$25.5M
Retained Earnings	-$458.8M-9.3%	-$419.8M-11.6%	-$376.1M-8.7%	-$345.9M-12.0%	-$308.7M-11.2%	-$277.5M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$141.6M-2.7%	$145.5M+8.0%	$134.7M-5.2%	$142.0M+0.8%	$140.9M+182.5%	$49.9M-48.5%	$96.8M-6.7%	$103.8M
Current Assets	$61.6M-5.1%	$64.9M+15.6%	$56.1M-7.5%	$60.7M+4.4%	$58.1M+195.9%	$19.6M-74.0%	$75.5M-7.8%	$81.9M
Cash & Equivalents	$28.1M+0.6%	$28.0M+155.0%	$11.0M-45.8%	$20.2M+9.6%	$18.5M-11.5%	$20.9M-51.1%	$42.6M-10.7%	$47.7M
Inventory	$4.3M+0.1%	$4.3M-12.6%	$4.9M+21.5%	$4.1M-4.2%	$4.2M-14.4%	$5.0M-19.2%	$6.1M-8.2%	$6.7M
Accounts Receivable	$16.5M-11.9%	$18.7M-28.4%	$26.1M-0.3%	$26.2M+12.2%	$23.4M+84.9%	$12.6M-26.3%	$17.1M-2.1%	$17.5M
Goodwill	$23.6M+4.2%	$22.7M+18.8%	$19.1M+2.4%	$18.6M0.0%	$18.6M	N/A	N/A	N/A
Total Liabilities	$115.3M+1.1%	$114.1M+10.6%	$103.1M+0.7%	$102.5M-6.1%	$109.1M-42.7%	$190.4M+145.9%	$77.4M+1.7%	$76.2M
Current Liabilities	$30.5M+5.5%	$28.9M+4.1%	$27.8M+11.9%	$24.8M-20.5%	$31.3M-16.5%	$37.5M+28.0%	$29.3M+101.8%	$14.5M
Long-Term Debt	$65.8M+0.2%	$65.7M+18.2%	$55.5M+0.4%	$55.3M+0.3%	$55.2M+19.9%	$46.0M-0.3%	$46.1M-22.4%	$59.4M
Total Equity	$22.4M-18.2%	$27.4M+0.8%	$27.1M-23.4%	$35.5M+28.0%	$27.7M+120.2%	-$136.9M-806.3%	$19.4M-29.9%	$27.7M
Retained Earnings	-$458.8M-1.6%	-$451.6M-2.0%	-$442.6M-2.3%	-$432.5M-3.0%	-$419.8M-59.2%	-$263.7M+33.0%	-$393.8M-2.6%	-$384.0M

STIM Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$20.4M+34.3%	-$31.0M+3.2%	-$32.0M-4.2%	-$30.7M-9.8%	-$28.0M+1.4%	-$28.4M
Capital Expenditures	$801K-45.4%	$1.5M-38.1%	$2.4M-27.5%	$3.3M+38.9%	$2.4M+222.3%	$730K
Free Cash Flow	-$21.2M+34.8%	-$32.5M+5.7%	-$34.4M-1.2%	-$34.0M-12.1%	-$30.3M-4.2%	-$29.1M
Investing Cash Flow	-$801K+66.8%	-$2.4M-82.5%	-$1.3M-119.6%	$6.7M+168.4%	-$9.8M-1247.8%	-$730K
Financing Cash Flow	$35.9M+626.6%	-$6.8M-130.0%	$22.7M+10864.7%	$207K-99.8%	$83.0M+3403.8%	$2.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$908K+215.7%	-$785K+77.6%	-$3.5M+79.4%	-$17.0M-97.7%	-$8.6M-58.7%	-$5.4M-9.0%	-$5.0M+58.6%	-$12.0M
Capital Expenditures	$216K+89.5%	$114K-54.8%	$252K+15.1%	$219K+146.1%	$89K-76.9%	$386K-37.3%	$616K+64.3%	$375K
Free Cash Flow	$692K+177.0%	-$899K+76.1%	-$3.8M+78.2%	-$17.2M-98.2%	-$8.7M-49.7%	-$5.8M-3.9%	-$5.6M+54.9%	-$12.4M
Investing Cash Flow	-$216K-89.5%	-$114K+54.8%	-$252K-15.1%	-$219K+90.8%	-$2.4M-17071.4%	$14K+111.8%	-$119K-275.0%	$68K
Financing Cash Flow	-$1.0M-105.7%	$17.9M+1790000.0%	$1K-100.0%	$19.0M+98.4%	$9.6M	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

STIM Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	48.5%-23.8pp	72.3%-0.2pp	72.5%-3.8pp	76.3%-2.7pp	78.9%+2.4pp	76.5%
Operating Margin	-21.1%+25.1pp	-46.2%-3.3pp	-42.8%+11.0pp	-53.8%-4.0pp	-49.8%-4.5pp	-45.3%
Net Margin	-26.2%+32.2pp	-58.4%-16.1pp	-42.3%+14.7pp	-57.0%-0.6pp	-56.4%-0.6pp	-55.8%
Return on Equity	-174.3%-16.5pp	-157.8%-69.5pp	-88.3%-23.2pp	-65.1%-28.5pp	-36.6%+71.1pp	-107.7%
Return on Assets	-27.6%+3.5pp	-31.0%-5.0pp	-26.1%+5.7pp	-31.8%-9.7pp	-22.1%+12.8pp	-34.9%
Current Ratio	2.02+0.2	1.86-2.9	4.73+1.8	2.98-4.4	7.34+2.6	4.75
Debt-to-Equity	2.94+1.0	1.99+0.3	1.73+1.3	0.40-0.0	0.41-0.9	1.36
FCF Margin	-14.2%+29.1pp	-43.4%+4.9pp	-48.2%+3.9pp	-52.1%+2.7pp	-54.9%+4.3pp	-59.1%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	51.9%+6.1pp	45.9%-0.7pp	46.6%-2.6pp	49.2%-17.0pp	66.2%-9.4pp	75.6%+1.5pp	74.0%-1.1pp	75.1%
Operating Margin	-12.1%+7.6pp	-19.6%+1.5pp	-21.1%+13.3pp	-34.4%+16.5pp	-51.0%-9.3pp	-41.7%+10.0pp	-51.7%-12.3pp	-39.4%
Net Margin	-17.1%+7.1pp	-24.3%+2.3pp	-26.6%+13.1pp	-39.6%+16.6pp	-56.3%+15.7pp	-72.0%-12.2pp	-59.8%-14.6pp	-45.2%
Return on Equity	-32.0%+1.1pp	-33.1%+4.2pp	-37.3%-1.5pp	-35.8%+10.0pp	-45.7%	N/A	-50.7%-22.2pp	-28.5%
Return on Assets	-5.1%+1.2pp	-6.2%+1.3pp	-7.5%+1.4pp	-8.9%+0.1pp	-9.0%+17.8pp	-26.8%-16.6pp	-10.2%-2.6pp	-7.6%
Current Ratio	2.02-0.2	2.24+0.2	2.02-0.4	2.44+0.6	1.86+1.3	0.52-2.1	2.58-3.1	5.65
Debt-to-Equity	2.94+0.5	2.40+0.4	2.05+0.5	1.56-0.4	1.99+2.3	-0.34-2.7	2.38+0.2	2.15
FCF Margin	1.7%+4.1pp	-2.4%+7.4pp	-9.9%+44.0pp	-53.8%-15.2pp	-38.6%-7.3pp	-31.3%+2.6pp	-34.0%+37.2pp	-71.1%

Similar Companies

TriSalus Life Sciences Inc. TLSI

$256.3M

Cvrx, Inc. CVRX

$239.4M

BioSig Technologies Inc BSGM

$157.0M

Electromed ELMD

$195.7M

Brainsway Ltd. BWAY

$543.6M

Frequently Asked Questions

What is Neuronetics's annual revenue?

Neuronetics (STIM) reported $149.2M in total revenue for fiscal year 2025. This represents a 99.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Neuronetics's revenue growing?

Neuronetics (STIM) revenue grew by 99.2% year-over-year, from $74.9M to $149.2M in fiscal year 2025.

Is Neuronetics profitable?

No, Neuronetics (STIM) reported a net income of -$39.0M in fiscal year 2025, with a net profit margin of -26.2%.

What is Neuronetics's EBITDA?

Neuronetics (STIM) had EBITDA of -$28.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Neuronetics have?

As of fiscal year 2025, Neuronetics (STIM) had $28.1M in cash and equivalents against $65.8M in long-term debt.

What is Neuronetics's gross margin?

Neuronetics (STIM) had a gross margin of 48.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Neuronetics's operating margin?

Neuronetics (STIM) had an operating margin of -21.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Neuronetics's net profit margin?

Neuronetics (STIM) had a net profit margin of -26.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Neuronetics's return on equity (ROE)?

Neuronetics (STIM) has a return on equity of -174.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Neuronetics's free cash flow?

Neuronetics (STIM) generated -$21.2M in free cash flow during fiscal year 2025. This represents a 34.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Neuronetics's operating cash flow?

Neuronetics (STIM) generated -$20.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Neuronetics's total assets?

Neuronetics (STIM) had $141.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Neuronetics's capital expenditures?

Neuronetics (STIM) invested $801K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Neuronetics spend on research and development?

Neuronetics (STIM) invested $6.6M in research and development during fiscal year 2025.

How many shares does Neuronetics have outstanding?

Neuronetics (STIM) had 69M shares outstanding as of fiscal year 2025.

What is Neuronetics's current ratio?

Neuronetics (STIM) had a current ratio of 2.02 as of fiscal year 2025, which is generally considered healthy.

What is Neuronetics's debt-to-equity ratio?

Neuronetics (STIM) had a debt-to-equity ratio of 2.94 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Neuronetics's return on assets (ROA)?

Neuronetics (STIM) had a return on assets of -27.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Neuronetics's cash runway?

Based on fiscal year 2025 data, Neuronetics (STIM) had $28.1M in cash against an annual operating cash burn of $20.4M. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Neuronetics's Piotroski F-Score?

Neuronetics (STIM) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Neuronetics's earnings high quality?

Neuronetics (STIM) has an earnings quality ratio of 0.52x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Neuronetics cover its interest payments?

Neuronetics (STIM) has an interest coverage ratio of -4.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Neuronetics?

Neuronetics (STIM) scores 30 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.